In vitro antifungal susceptibility of candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3646-3649

  Fernańdez Silva, Fabiola ^a   Lackner, Michaela ^b   Capilla, Javier ^a   Mayayo, Emilio ^a   Sutton, Deanna ^c   Castanheira, Mariana ^d   Fothergill, Annette W ^c   Lass Flörl, Cornelia ^b   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; 1,3-BETA-GLUCAN SYNTHASE; ANTIFUNGAL AGENT; FUNGAL PROTEIN; GLUCOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; FKS GENE; FUNGAL STRAIN; GENE; GENE MUTATION; IMMUNE DEFICIENCY; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MURINE MODEL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; GENETICS; KIDNEY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; KIDNEY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; SURVIVAL RATE;

EID: 84903127952     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02666-13     Document Type: Article

References (39)

1. Pfaller M, Diekema D. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. http://dx.doi.org/10.1128/CMR.00029-06. (Pubitemid 46167771)
2. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. Diagn. Microbiol. Infect. Dis. 74:323-331. http://dx.doi.org/10.1016/j. diagmicrobio.2012.10.003.
3. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B, Rosenvinge FS, Røder BL, Schønheyder HC. 2013. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin. Microbiol. Infect. 19:343-353. http://dx.doi.org/10.1111/1469-0691.12212.
4. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
5. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. 2012. ESCMID*guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 18:53-67. http://dx.doi.org/10. 1111/1469-0691.12041.
6. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8. (Pubitemid 37222342)
7. Zaas AK, Dodds Ashley ES, Alexander BD, Johnson MD, Perfect JR. 2006. Caspofungin for invasive candidiasis at a tertiary care medical center. Am. J. Med. 119:993e1-993e6. http://dx.doi.org/10.1016/j.amjmed.2006.02.029.
8. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894. http://dx.doi.org/10.1128/AAC.00349- 06. (Pubitemid 44198725)
9. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265. http://dx.doi.org/10.1128/AAC.01568-07. (Pubitemid 351758575)
10. Thompson GR, III, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, Jr, Patterson TF. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785. http://dx.doi.org/10.1128/AAC.00473- 08.
11. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55: 532-538. http://dx.doi.org/10.1128/AAC.01128-10.
12. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int. J. Antimicrob. Agents 38:65-69. http://dx.doi.org/10.1016/j.ijantimicag. 2011.02.016.
13. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J. Clin. Microbiol. 50:3435-3442. http://dx.doi.org/10.1128/JCM.01283-12.
14. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob. Agents Chemother. 56:6304-6309. http://dx.doi.org/10.1128/AAC.00813- 12.
15. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002. (Pubitemid 47031054)
16. Ostrosky-Zeichner L. 2013. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin. Infect. Dis. 56:1733-1734. http://dx.doi.org/10.1093/cid/cit140.
17. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
18. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 2014. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses http://dx.doi.org/10.1111/ myc.12170.
19. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10. 1128/AAC.01519-13.
20. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Lackner M, Najafzadeh MJ, Sun J, Lu Q, Hoog GS. 2012. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl. Environ. Microbiol. 78:126-133. http://dx.doi.org/ 10.1128/AEM.05280-11.
22. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659. http://dx.doi.org/10.1128/AAC.01711-09.
23. Ortoneda M, Capilla J, Pastor FJ, Serena C, Guarro J. 2004. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn. Microbiol. Infect. Dis. 50:247-251. http://dx.doi.org/10.1016/j.diagmicrobio. 2004.07.011. (Pubitemid 39593147)
24. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
25. Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW. 2011. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob. Agents Chemother. 55:4880-4887. http://dx.doi.org/10.1128/AAC.00621-11.
26. Spreghini E, Orlando F, Sanguinetti M, Posteraro B, Giannini D, Manso E, Barchiesi F. 2012. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob. Agents Chemother. 56:1215-1222. http://dx.doi.org/10.1128/AAC.05872-11.
27. Espinel-Ingroff A, Cantón E. 2011. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? Enferm. Infecc. Microbiol. Clin. 29:3-9. http://dx.doi.org/10.1016/ S0213-005X(11)70002-7.
28. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCAST-AFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 8:246-247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
29. Arendrup MC, Pfaller MA, Danish Fungaemia Study Group. 2012. Caspofungin E-test susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355-12.
30. Alastruey-Izquierdo A, Gómez-López A, Arendrup MC, Lass Flörl C, Hope WW, Perlin DS, Rodriguez-Tudela JL, Cuenca-Estrella M. 2012. Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J. Clin. Microbiol. 50:2509-2512. http://dx.doi.org/10.1128/JCM.00791-12.
31. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44: 2310-2318. http://dx.doi.org/10.1128/AAC.44.9.2310-2318.2000. (Pubitemid 30650873)
32. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. 2005. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother. 49:4895-4902. http://dx.doi.org/10.1128/AAC.49.12.4895-4902.2005. (Pubitemid 41778899)
33. Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G. 2005. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49: 4989-4992. http://dx.doi.org/10.1128/AAC.49.12.4989-4992.2005. (Pubitemid 41778910)
34. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54: 2497-2506. http://dx.doi.org/10.1128/AAC.01584-09.
35. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather thanMICis an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56:4862-4869. http://dx.doi.org/10.1128/AAC.00027-12.
36. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. 2012. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without FKS mutations. Antimicrob. Agents Chemother. 56: 5875-5882. http://dx.doi.org/10. 1128/AAC.01102-12.
37. Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN, Pfaller M. 2014. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob. Agents Chemother. 58:577-580. http://dx.doi.org/10.1128/AAC.01674-13.
38. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047. http://dx.doi.org/10.1128/AAC.00836-10.
39. Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen YL, Poutanen SM, Rennie RP, Heitman J, Cowen LE. 2012. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 8:e1002718. http://dx.doi.org/10.1371/journal.ppat.1002718.